## (THE DRUGS & COSMETICS ACT 1940 & RULES THEREUNDER)

Sample Name OFLOXACIN & ORNIDAZOLE TABLETS-IP.

03/2023

Submitted By Quality Control Advisor. (MMDSL) Shillong.

Address Mfg By

Supplied By N.S.

Batch No MMDSL/QC-0146

DHS LaitumkhrahNHM, EastKhasi Hills Meghalaya.

Mfg. Date

Exp Date 02/2025

Ref No Batch Size N.S.

Mfg Lic No

Report Date

Receipt Date 19-Mar-24

Report No

Sample Qty 60 TABS.

N.S.

29-Mar-24

## **RESULT OF ANALYSIS**

Date / Period of Performance of test 19/03/2024 to 29/03/2024.

Reference to protocol

:- IP-2022.

Description

:- Orange coloured elongated biconvex film coated

tablet.

Identification (By HPLC)

:- Complies.

Average weight

:- 845.0mg.

Uniformity of weight

:- Within limit.

Related substances(by HPLC) :- Complies.

Dissolution (by HPLC)

For Ofloxacin For Ornidazole :- Complies (88.26% to 94.73%) :- Complies (89.17% to 95.48%)

NLT-75% + 5% NLT-75% + 5%

Upper

· Limit

Assay (by HPLC)

:- Each film coated tablet contains:-

LIMIT

Contents of

Obtd./Av.wt. :- 199.16mg

Claim 200.0mg.

180.0mg.

Lower

220.0mg. IP.

Method

Ofloxacin Ornidazole

:- 498.67mg

500.0mg

450.0mg

550.0mg IP.

NOTE: - SAMPLE CONSUMED IN TESTING.

Report: In Opinion of the undersigned, The sample referred to above is of Standard Quality as defined in the Act and the rules made there under for the reason given: Complies as per IP.

NOTE: 1. The result listed refer only to the tested samples and applicable parameter. Endorsement of products is neither inferred nor implied.

2. Sample not drawn by us. Total liability of this laboratory limited to the invoice amount.

3. This report is not be reproduced wholly or in part and cannot be used as an evidence in the Court of Law and should not be used in any advertising media without special permission in writing.